Xenetic Biosciences (XBIO) Competitors $9.46 -0.90 (-8.69%) Closing price 04:00 PM EasternExtended Trading$9.57 +0.11 (+1.15%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsOwnershipSEC FilingsShort InterestTrendsBuy This Stock XBIO vs. LPTX, MTVA, ALLR, PASG, PRPH, TAOX, MIRA, NNVC, MBRX, and CTXRShould you be buying Xenetic Biosciences stock or one of its competitors? The main competitors of Xenetic Biosciences include Leap Therapeutics (LPTX), MetaVia (MTVA), Allarity Therapeutics (ALLR), Passage Bio (PASG), ProPhase Labs (PRPH), Synaptogenix (TAOX), MIRA Pharmaceuticals (MIRA), NanoViricides (NNVC), Moleculin Biotech (MBRX), and Citius Pharmaceuticals (CTXR). These companies are all part of the "pharmaceutical products" industry. Xenetic Biosciences vs. Its Competitors Leap Therapeutics MetaVia Allarity Therapeutics Passage Bio ProPhase Labs Synaptogenix MIRA Pharmaceuticals NanoViricides Moleculin Biotech Citius Pharmaceuticals Leap Therapeutics (NASDAQ:LPTX) and Xenetic Biosciences (NASDAQ:XBIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation. Which has higher earnings and valuation, LPTX or XBIO? Xenetic Biosciences has higher revenue and earnings than Leap Therapeutics. Xenetic Biosciences is trading at a lower price-to-earnings ratio than Leap Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLeap TherapeuticsN/AN/A-$67.56M-$1.58-0.43Xenetic Biosciences$2.45M5.96-$3.96M-$2.00-4.73 Is LPTX or XBIO more profitable? Leap Therapeutics has a net margin of 0.00% compared to Xenetic Biosciences' net margin of -126.08%. Xenetic Biosciences' return on equity of -54.56% beat Leap Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Leap TherapeuticsN/A -237.65% -155.38% Xenetic Biosciences -126.08%-54.56%-47.28% Which has more risk & volatility, LPTX or XBIO? Leap Therapeutics has a beta of -0.05, meaning that its share price is 105% less volatile than the S&P 500. Comparatively, Xenetic Biosciences has a beta of 2.42, meaning that its share price is 142% more volatile than the S&P 500. Does the media favor LPTX or XBIO? In the previous week, Leap Therapeutics had 2 more articles in the media than Xenetic Biosciences. MarketBeat recorded 6 mentions for Leap Therapeutics and 4 mentions for Xenetic Biosciences. Leap Therapeutics' average media sentiment score of 0.59 beat Xenetic Biosciences' score of 0.48 indicating that Leap Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Leap Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Xenetic Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts rate LPTX or XBIO? Leap Therapeutics presently has a consensus target price of $3.38, indicating a potential upside of 391.98%. Given Leap Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Leap Therapeutics is more favorable than Xenetic Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Leap Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75Xenetic Biosciences 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Do institutionals and insiders believe in LPTX or XBIO? 30.5% of Leap Therapeutics shares are owned by institutional investors. Comparatively, 15.1% of Xenetic Biosciences shares are owned by institutional investors. 7.5% of Leap Therapeutics shares are owned by company insiders. Comparatively, 14.7% of Xenetic Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. SummaryLeap Therapeutics beats Xenetic Biosciences on 8 of the 14 factors compared between the two stocks. Get Xenetic Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding XBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XBIO vs. The Competition Export to ExcelMetricXenetic BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$15.98M$2.65B$6.14B$10.65BDividend YieldN/A56.72%5.66%4.70%P/E Ratio-4.7323.7585.8427.65Price / Sales5.96782.57621.60138.35Price / CashN/A177.3038.3262.20Price / Book2.435.6413.066.79Net Income-$3.96M$32.78M$3.30B$275.88M7 Day Performance187.54%6.31%4.81%2.64%1 Month Performance210.67%13.80%9.99%9.13%1 Year Performance133.58%2.75%85.28%35.89% Xenetic Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XBIOXenetic Biosciences0.761 of 5 stars$9.46-8.7%N/A+153.3%$15.98M$2.45M-4.734Analyst ForecastGap DownLPTXLeap Therapeutics2.575 of 5 stars$0.63-18.0%$3.38+438.8%-68.7%$25.96MN/A-0.4040News CoverageAnalyst ForecastHigh Trading VolumeMTVAMetaVia3.0219 of 5 stars$1.06-1.9%$7.50+607.5%N/A$25.65MN/A0.008Analyst ForecastALLRAllarity Therapeutics2.7343 of 5 stars$1.75+6.1%$9.25+428.6%+6.2%$25.41MN/A0.0010Analyst ForecastPASGPassage Bio3.644 of 5 stars$7.95+0.3%$75.67+851.8%-32.4%$25.27MN/A-0.44130Analyst ForecastPRPHProPhase Labs0.3595 of 5 stars$0.61+2.1%N/A-77.8%$25.25M$6.77M-0.48130Analyst ForecastGap UpTAOXSynaptogenix0.0504 of 5 stars$7.22-6.4%N/AN/A$25.20MN/A-0.364News CoverageAnalyst ForecastGap UpMIRAMIRA Pharmaceuticals0.9463 of 5 stars$1.31-3.0%N/A+20.0%$24.98MN/A-2.672Analyst ForecastNNVCNanoViricides0.2925 of 5 stars$1.42-2.4%N/A+0.7%$24.67MN/A-1.9720MBRXMoleculin Biotech3.0911 of 5 stars$0.49+0.6%$4.00+724.7%-79.7%$24.01MN/A0.0020Analyst ForecastCTXRCitius Pharmaceuticals2.7112 of 5 stars$1.40+5.3%$53.00+3,685.7%-86.8%$23.82MN/A0.0020Analyst ForecastGap UpHigh Trading Volume Related Companies and Tools Related Companies LPTX Competitors MTVA Competitors ALLR Competitors PASG Competitors PRPH Competitors TAOX Competitors MIRA Competitors NNVC Competitors MBRX Competitors CTXR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XBIO) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenetic Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenetic Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
